U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C25H27ClN2.ClH
Molecular Weight 427.409
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MECLIZINE MONOHYDROCHLORIDE

SMILES

Cl.CC1=CC=CC(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)=C1

InChI

InChIKey=GJNMJOHYRWHJQB-UHFFFAOYSA-N
InChI=1S/C25H27ClN2.ClH/c1-20-6-5-7-21(18-20)19-27-14-16-28(17-15-27)25(22-8-3-2-4-9-22)23-10-12-24(26)13-11-23;/h2-13,18,25H,14-17,19H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula C25H27ClN2
Molecular Weight 390.948
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/meclizine.html

Meclizine, a piperazine-derivative H1-receptor antagonist similar to buclizine, cyclizine, and hydroxyzine, is used as an antivertigo/antiemetic agent. Meclizine is used in the management of nausea, vomiting, and dizziness associated with motion sickness and vertigo in diseases affecting the vestibular apparatus. Along with its actions as an antagonist at H1-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone. It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine II.

CNS Activity

Curator's Comment: central nervous system depressant

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q922E4
Gene ID: 68671.0
Gene Symbol: Pcyt2
Target Organism: Mus musculus (Mouse)
31.0 µM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ANTIVERT

Approved Use

Effective: Management of nausea and vomiting, and dizziness associated with motion sickness. Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system.

Launch Date

2012
Primary
ANTIVERT

Approved Use

Effective: Management of nausea and vomiting, and dizziness associated with motion sickness. Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system.

Launch Date

2012
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
99.43 ng/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
564.03 ng × h/mL
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.24 h
25 mg single, oral
dose: 25 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
MECLIZINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
25 mg 2 times / day multiple, oral
Recommended
Dose: 25 mg, 2 times / day
Route: oral
Route: multiple
Dose: 25 mg, 2 times / day
Sources:
unhealthy, 5-10
n = 6
Health Status: unhealthy
Condition: Achondroplasia
Age Group: 5-10
Sex: M+F
Population Size: 6
Sources:
25 mg single, oral
Recommended
Dose: 25 mg
Route: oral
Route: single
Dose: 25 mg
Sources:
unhealthy, 6-10
n = 6
Health Status: unhealthy
Condition: Achondroplasia
Age Group: 6-10
Sex: M+F
Population Size: 6
Sources:
100 mg multiple, oral (total daily dose)
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Vertigo
Sources: Page: p.1
Other AEs: Drowsiness...
AEs

AEs

AESignificanceDosePopulation
Drowsiness
100 mg multiple, oral (total daily dose)
Recommended
Dose: 100 mg
Route: oral
Route: multiple
Dose: 100 mg
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Vertigo
Sources: Page: p.1
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Drug-induced extrapyramidal signs in chronic liver disease--a case report.
1977
Clofibrate myopathy: a case report and a review of the literature.
1986 Feb
Memory loss, confusion, and disorientation in an elderly woman taking meclizine.
1987 May
Central nervous system effects of meclizine and dimenhydrinate: evidence of acute tolerance to antihistamines.
1992 Nov
Pentoxifylline-induced musical hallucinations.
1993 Aug
Discovery of molecular mechanisms of neuroprotection using cell-based bioassays and oligonucleotide arrays.
2002 Oct 29
Auditory hallucinations elicited by combined meclizine and metaxalone use at bedtime.
2004 Nov
Effects of drug countermeasures for space motion sickness on working memory in humans.
2004 Nov-Dec
Use of antiemetic drugs during pregnancy in Sweden.
2005 Dec
Withdrawal symptoms after discontinuation of transdermal scopolamine therapy: treatment with meclizine.
2009 Nov 15
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.
2013 Sep 5
Patents

Patents

Sample Use Guides

Usual Adult Dose for Vertigo -25 to 100 mg orally per day in divided doses Usual Adult Dose for Motion Sickness -Initial Dose: 25 to 50 mg orally 1 hour before travel -Maintenance Dose: Repeat dose every 24 hours if needed
Route of Administration: Oral
50 uM meclizine inhibited respiratory growth of human skin fibroblasts
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:00:39 GMT 2023
Edited
by admin
on Fri Dec 15 17:00:39 GMT 2023
Record UNII
008PUV3986
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MECLIZINE MONOHYDROCHLORIDE
Common Name English
PIPERAZINE, 1-((4-CHLOROPHENYL)PHENYLMETHYL)-4-((3-METHYLPHENYL)METHYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
MECLOZINE MONOHYDROCHLORIDE
Common Name English
MECLOZINE HYDROCHLORIDE
Common Name English
ANHYDROUS MECLOZINE HYDROCHLORIDE
Common Name English
PIPERAZINE, 1-((4-CHLOROPHENYL)PHENYLMETHYL)-4-((3-METHYLPHENYL)METHYL)-, MONOHYDROCHLORIDE
Systematic Name English
MECLIZINE MONOHYDROCHLORIDE ANHYDROUS
Common Name English
Code System Code Type Description
SMS_ID
100000092183
Created by admin on Fri Dec 15 17:00:39 GMT 2023 , Edited by admin on Fri Dec 15 17:00:39 GMT 2023
PRIMARY
FDA UNII
008PUV3986
Created by admin on Fri Dec 15 17:00:39 GMT 2023 , Edited by admin on Fri Dec 15 17:00:39 GMT 2023
PRIMARY
PUBCHEM
92303
Created by admin on Fri Dec 15 17:00:39 GMT 2023 , Edited by admin on Fri Dec 15 17:00:39 GMT 2023
PRIMARY
CAS
410538-37-3
Created by admin on Fri Dec 15 17:00:39 GMT 2023 , Edited by admin on Fri Dec 15 17:00:39 GMT 2023
PRIMARY
EVMPD
SUB26432
Created by admin on Fri Dec 15 17:00:39 GMT 2023 , Edited by admin on Fri Dec 15 17:00:39 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY